Aug 22,2022

With Tailored, Fit-for-Purpose RWD from COTA, Life Science Companies Can Drive Innovation

Deeply curated, targeted oncology datasets are often hard to find, especially for life science companies on the leading edge of innovation. COTA's cancer-specific data product Vantage© offers flexible, customized, and de-identified data to equip researchers with fit-for-purpose real-world data. With deeply curated, disease-specific, large scale data sets from our Vantage© product, life science companies can leverage de-identified EHR data for a variety of high-value projects, including informing the direction of new products, conducting health economics and outcomes research, supporting regulatory submissions via external control and comparator arms (ECAs), and demonstrating value and safety in the post-market environment.

PRODUCT

#rwd

#big data

View Analyst & Ambassador Comments
Go to original news
Sep 01,2022

Flatiron Health Announces Nature Digital Medicine Publication of Machine Learning Development and Evaluation Framework Supporting Prospective Clinical Decisions Applied to Risk Prediction in Oncology

Flatiron Health announced the publication in Nature Digital Medicine of evidence from a machine learning (ML) approach that demonstrates the value of a ML-based clinical tool that can be used to support a clinician’s independent assessment of patient risk, using EHR-derived RWD, to avoid acute care events.

#rwd

#ml

View Analyst & Ambassador Comments
Go to original news
Sep 14,2022

RCTs and RWD: What are They and How do They Complement Each Other in Cancer Research?

Real world data (RWD) is transforming clinical development and it is critical to understand how RWD and randomized clinical trials (RCTs) can work together to bring life saving medicines to patients faster. In this new blog series from COTA and Deloitte, they explore the expanding role of RWD in oncology.

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Oct 06,2022

Massive Bio and Perthera.ai Partner to Empower Cancer Patients with Personalized Therapies and Accurate Trial Recommendations

Massive Bio, a leader in AI-powered cancer clinical trial enrollment, announced a strategic partnership with Perthera.ai, a pioneer in connecting oncologists and patients with biomarker-based therapy options. By combining the advanced computational methods and artificial intelligence capabilities of both companies, more physicians and patients will be able to confidently access the benefits of investigational precision oncology treatments from FDA-approved and novel therapies that are specific to patients’ unique molecular and genetic biomarkers. Perthera.ai combines multi-omic testing results (DNA, RNA, IHC and phosphoproteomics) to advise oncologists and their patients and simplify the decision-making process to increase the chance that the best therapy is used the first time.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 16,2021

COTA, Inc. and Kite Collaborate To Expand the Use of Real-World Data To Drive Faster, Effective Treatments for Cancers

COTA, Inc., an oncology real-world data and analytics company, today announced a collaboration with Kite, a Gilead company, through which COTA’s real-world data will be used to accelerate Kite’s drug development pipeline. This approach will help inform decisions about future therapeutic applications for blood cancers while inspiring new ways of thinking about how clinical trials are designed.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Apr 22,2022

Clinical Outcomes Solutions and Carevive Systems Partner to Improve the Patient Experience in Cancer Care

Clinical Outcomes Solutions today announced a collaborative partnership with Carevive Systems, the leading oncology-focused health technology company. The two organizations, both deeply experienced with the collection and analysis of oncology data, are proud to announce that Carevive is joining the Oncology Outcomes initiative, launched in February 2019, to deliver world-class data and analysis to improve the patient experience and enhance survival outcomes of cancer patients. The partnership will leverage Carevive’s innovative digital oncology platform to capture the patient experience while on treatment, and COS’ deep experience in analyzing these types of data, providing invaluable insights for life science companies and regulatory authorities.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rpm

View Analyst & Ambassador Comments
Go to original news
May 20,2021

2021 ASCO Annual Meeting Publishes Two Abstracts Based on Real-World Patient Data Generated from Belong.Life's Connected Health Platform

Belong.Life, developer of social and professional networks for managing and navigating diseases, and the creator of the world's largest social network for cancer patients, today announced that the American Society of Clinical Oncology (ASCO) has published two abstracts in its 2021 Annual Meeting Abstract Book based on data aggregated from the Belong Beating Cancer Together app. The abstracts provide key insights into significant challenges for oncology patients, including sexuality and clinical trial participation.

CLINICAL STUDY

#mobile app

#rwd

View Analyst & Ambassador Comments
Go to original news
May 01,2021

Leading Real-World Data and Analytics Organizations Form Industry Coalition to Advance Policies to Support Regulatory Use of Real-World Evidence

Five real-world data (RWD) and analytics organizations today announced an industry coalition dedicated to advancing the use of real-world evidence (RWE) to support regulatory decisions. Founding members of the RWE Alliance are Aetion, Flatiron Health, IQVIA, Syapse, and Tempus.

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 22,2021

Real-World Data Providing Insights on Patient Management, Treatment Experience

Collecting and analyzing real-world data helps to both better understand disease and monitor medical practice and overall care with the aim of improving outcomes for patients. New real-world evidence from three clinical practice studies presented at ASCO showed how physicians play important roles in patient well-being that go beyond cancer treatment itself. The presented studies provided insights into important issues affecting breast cancer patients, including BRCA testing, financial toxicity, and treatment delays.

PRODUCT

#mobile app

#rwd

View Analyst & Ambassador Comments
Go to original news
Jul 01,2021

Flatiron Health Real-World Data Support FDA Approval of New Dosing Regimen for ERBITUX® (cetuximab)

Flatiron Health real-world data (RWD) supported the U.S. Food and Drug Administration (FDA)’s recent approval of a new dosing regimen for ERBITUX®(Eli Lilly and Company’s cetuximab) that can have a direct positive impact on the lives of patients with metastatic colorectal cancer (CRC) or squamous cell carcinoma of the head and neck (SCCHN).

#rwd

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD